Clinical Trial Underrepresentation in Africa

How it works

Comparisons

Background

Evidence quality

Highlighted claims

• Low- and middle-income countries, especially in Africa, account for fewer than 3% of the world's clinical trials despite carrying the largest global disease burden. — Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol
• Africa's clinical research environment has historically been labelled 'not conducive' to clinical investigation, with insufficient human resources and limited commercial viability as root causes. — Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol
• Early research phases in Africa are often conducted elsewhere, disconnected from local health contexts. — Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol
• Africa is increasingly positioned as an emerging destination for clinical research. — Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol
• The creation of the African Medicines Agency and regional harmonisation initiatives are gradually unlocking the continent's research potential. — Three decades of clinical trials in Portuguese-speaking Africa: a comprehensive scoping review protocol